Myotonic dystrophy (DM)-the most common form of muscular dystrophy in adults, affecting 1/8,000 individuals-is a dominantly inherited disorder with a peculiar and rare pattern of multisystemic clinical features affecting skeletal muscle, the heart, the eye, and the endocrine system. Two genetic loci have been associated with the DM phenotype: DM1, on chromosome 19, and DM2, on chromosome 3. In 1992, the mutation responsible for DM1 was identified as a CTG expansion located in the 3 untranslated region of the dystrophia myotonica-protein kinase gene (DMPK). How this untranslated CTG expansion causes myotonic dystrophy type 1(DM1) has been controversial. The recent discovery that myotonic dystrophy type 2 (DM2) is caused by an untranslated CCTG expansion, along with other discoveries on DM1 pathogenesis, indicate that the clinical features common to both diseases are caused by a gain-of-function RNA mechanism in which the CUG and CCUG repeats alter cellular function, including alternative splicing of various genes. We discuss the pathogenic mechanisms that have been proposed for the myotonic dystrophies, the clinical and molecular features of DM1 and DM2, and the characterization of murine and cell-culture models that have been generated to better understand these diseases.
Introduction
and Batten and Gibb (1909) identified myotonic dystrophy (DM [MIM 160900 and MIM 602668]) as a multisystemic disorder that is now recognized as one of the most common forms of muscular dystrophy in adults. In addition to muscular dystrophy and myotonia (involuntary persistence of muscle contraction), DM causes a consistent constellation of seemingly unrelated and rare clinical features, including: cardiac conduction defects, posterior subcapsular iridescent cataracts, and a peculiar and specific set of endocrine changes (Harper 2001) . The 90 years between the identification of myotonic dystrophy as a clinical disorder and the identification of the first gene were important for the development of a detailed description of the clinical features, inheritance, and epidemiology of myotonic dystrophy. Clinical neurologists and geneticists identified non-Mendelian features of myotonic dystrophy type 1 (DM1) inheritance, including variable penetrance, anticipation (a tendency for the disease to worsen in subsequent generations), and a maternal transmission bias for congenital forms (Harper 2001) , all of which preceded the identification of the CTG expansion respon-sible for DM1. The genetic cause of DM1 was identified in 1992 as a (CTG)n repeat in the 3 -UTR of a protein kinase gene Buxton et al. 1992; Fu et al. 1992; Harley et al. 1992; Mahadevan et al. 1992). In 1995, several reports described families with dominantly inherited multisystemic myotonic disorders that were genetically distinct from DM1 (Ricker et al. 1994; Rowland 1994 ; Thornton et al. 1994 ). Ricker and colleagues (1994) most thoroughly evaluated this new disorder and showed that the genetic cause in these families was distinct from the known causes of myotonia congenita, paramyotonia, and DM1, demonstrating the existence of a novel genetic disorder. Because affected family members often came to medical attention because of pelvic girdle weakness, he referred to the disorder as "proximal myotonic myopathy" (PROMM). A broader phenotype was described as "proximal myotonic dystrophy" in 1997 (Udd et al. 1997 ). Subsequently, we reported a large Minnesota kindred with a second form of myotonic dystrophy (DM2) that closely mimics the phenotype of adult-onset DM1, and we localized the disease gene to a 10-cM region on chromosome 3q (Ranum et al. 1998; Day et al. 1999 ). Ricker and colleagues then reported that the gene for PROMM in many families also mapped to the DM2 locus . The International Myotonic Dystrophy Consortium (IDMC 2000) and the Online Mendelian Inheritance in Man (OMIM) database updated the clinical and scientific nomenclature so that the chromosome 19 locus is now referred to as "myotonic dystrophy type 1" (DM1) and the locus on chromosome 3 to which DM2 and many PROMM families map is the DM2 locus. The diseases are collectively referred to as "the myotonic dystrophies" (DM), and each individual genetic disorder is referred to by the same name as the locus name (DM1, DM2), whereas "PROMM" can be used to describe the clinical presentation but is not restricted to any specific genetic cause or locus.
Clinical Features

Muscle Dysfunction
The multisystemic nature of DM results in varied symptoms in affected individuals (table 1) , although almost all affected individuals have clinically identifiable muscle involvement at the time of diagnosis. Muscle dysfunction is the most common presenting complaint in both DM1 and DM2 (Moxley 1996; Day et al. 1999 Day et al. , 2003 Ricker 1999; Thornton 1999; Harper 2001) , with symptomatic weakness, pain and myotonia. Myotonia is involuntary muscle contraction and delayed relaxation due to muscle hyperexcitability.
There are similarities and differences in the muscle features of DM1 and DM2. Both diseases result in early clinically detectable weakness of neck flexors and lateral deep finger flexors (Moxley 1996; Day et al. 1999; Mathieu et al. 1999; Ricker 1999; Thornton 1999; Harper 2001; Day et al. 2003) , although initial symptoms in DM2 often involve proximal lower extremity musculature, whereas DM1 is more apt to be associated with severe muscle atrophy and symptomatic finger flexor weakness. DM2 is not associated with severely atrophic facial and forearm muscles. Electrical myotonia is detectable by electromyography in almost all individuals with DM1 or DM2; although clinical symptoms of myotonia are not typically severe in either disease, patients with DM1 are often more symptomatic than those with DM2.
The histological features of DM muscle are distinct, though not pathognomonic, with dystrophic features accompanied by atrophic fibers, scattered severely atrophic fibers with pyknotic myonuclei, and a marked proliferation of fibers with central nuclei. There is one report of differences in fiber-type involvement in the two diseases, with more type 1 involvement in DM1 and more type 2 involvement in DM2 (Vihola et al. 2003) .
Multisystemic Features
DM1 and DM2 have similar disease-specific effects on the eye, heart, and endocrine systems. Ocular involvement results in almost all adults with DM1 or DM2 having posterior subcapsular cataracts, with distinctive red and green iridescent opacities on slitlamp examination. Some adults are unaffected by these cataracts, but other subjects with DM1 or DM2 may require lens removal as early as the 2nd decade of life (Harper 2001; Day et al. 2003) . Cardiac involvement leads to conduction defects, arrhythmias, and sudden death in both DM1 and DM2 (Nguyen et al. 1988; Colleran et al. 1997; Merino et al. 1998; Philips et al. 1998; Day et al. 2003) but does not correlate with severity of skeletal muscle involvement or repeat length (Lazarus et al. 1999) . Endocrine abnormalities in both DM1 and DM2 result in hyperinsulinemia, hyperglycemia, and insulin insensitivity, with type 2 diabetes occurring in each disorder (Harper 2001; Day et al. 2003) . Testicular failure is also common in both disorders, with associated hypotestosteronism, elevated follicle-stimulating hormone (FSH) levels, and oligospermia. Other serological abnormalities in both disorders include reduced levels of immunoglobulin G and M (Harper 2001; Day et al. 2003) .
Congenital Myotonic Dystrophy
A primary difference between DM1 and DM2 is that DM1 can result in a severe congenital form that has not been reported for DM2. The congenital form of DM1 involves marked developmental abnormalities that can be present to a lesser degree in patients with DM1 who become symptomatic during adulthood; the hallmark developmental features, including craniofacial skeletal abnormalities, characteristic dysmorphic features, and mental retardation, have not been reported in DM2.
CNS Involvement
CNS involvement in DM1 involves both (1) developmental abnormalities with retardation and (2) degenerative changes, exemplified by abnormal white matter changes on MRI scanning, memory deficits, and personality abnormalities (Rubinsztein et al. 1997; Bun-gener et al. 1998; Delaporte 1998; Ogata et al. 1998; Ono et al. 1998; Wilson et al. 1999) . The CNS effects of DM2 mirror the degenerative changes of DM1, including the MRI abnormalities (Hund et al. 1997 ), but developmental abnormalities and retardation are not recognized features of DM2 .
DM1 (CTG)n Repeat Expansion and Instability
In 1992, the chromosome 19 form of DM was shown to be caused by an expanded CTG repeat located in the 3 UTR of the myotonia-dystrophica protein kinase (DMPK [MIM 605377]) gene Buxton et al. 1992; Fu et al. 1992; Harley et al. 1992; Mahadevan et al. 1992 ) and the promoter region of the immediately adjacent homeodomain gene SIX5 (MIM 600963) (Boucher et al. 1995) . DM1 was the first autosomal dominant disease found to be caused by an untranslated trinucleotide repeat expansion, in which the mutation is transcribed into RNA but not translated into protein. The CTG expansion in DM1 can vary from 50 to 14,000 repeats in affected individuals. Both intergenerational and somatic instability are observed with increases in repeat size on the order of ∼50-80 repeats per year (Monckton et al. 1995; Martorell et al. 1998 ). For DM1, there are reasonably good correlations of repeat size and age at onset for CTGs !400 repeats (Hamshere et al. 1999 ).
The DM1 CTG Expansion: Proposed Mechanisms of Pathogenesis
Haploinsufficiency of DMPK
Because most dominant disorders are caused by the expression of an abnormal protein with an altered function, it has not been clear how the multisystemic clinical features of dominantly inherited DM1 could be caused by a trinucleotide repeat that did not affect the protein coding portion of a gene (Tapscott 2000) . Initially, the location of the mutation at the 3 end of a kinase gene suggested that alterations in DMPK expression might cause the multisystemic clinical features of the disease. Most of the early expression studies were consistent with this hypothesis, indicating that DMPK mRNA and protein levels were reduced in patient muscle and cell culture (Fu et al. 1992; Hoffmann-Radvanyi et al. 1993; Novelli et al. 1993 ). However, DMPK knockout mice generated to test this hypothesis did not have the typical multisystemic features of the disease. Initial reports of these mice showed only a very mild, late-onset myopathy that is not typical of DM1 (Jansen et al. 1996; Reddy et al. 1996) . More recently, both hemizygous and homozygous DMPK knockout mice have been reported to have cardiac conduction abnormalities. When considered to-gether, these results suggested that DMPK may contribute to the cardiac features of DM1, but haploinsufficiency of DMPK does not cause the multisystemic clinical features of DM1. The fact that there are no reported cases of DM1 caused by point mutations in the DMPK gene further suggests that the multisystemic features of DM1 are not caused simply by DMPK haploinsufficiency.
Haploinsufficiency of SIX5 and Neighboring Genes
A second proposed mechanism is that the expanded repeat affects the expression of multiple genes in the region. Support for this hypothesis comes from the observation that the CTG expansion is a strong nucleosome-binding site that could potentially alter chromatin structure and have regional effects on the expression of multiple genes (Wang et al. 1994; Otten and Tapscott 1995) . The expansion overlaps not only the 3 end of DMPK, but the 5 promoter region of the neighboring gene SIX5. SIX5 has a strong resemblance to the fruit fly gene sine oculis (needed for eye development) and to a family of mouse genes that regulate distal limb muscle development. Because cataracts and distal muscle wasting are common in DM1, haploinsufficiency of SIX5 was suggested as a possible contributor to DM1 pathogenesis (Shaw et al. 1993; Boucher et al. 1995; Jansen et al. 1995) . In addition to DMPK and SIX5, other neighboring genes suggested to be involved in aspects of DM1 pathogenesis included the DMWD gene immediately upstream of DMPK, which is expressed in the testis and is proposed to play a role in male infertility, and FCGRT (MIM 601437), an IgG receptor gene located 4 Mb from the CTG expansion, was proposed to underlie the low IgG levels in DM (Junghans et al. 2001 ). In this model, the multisystemic features of DM1 would be explained by haploinsufficiency of a number of neighboring genes, with expression level-and, hence, disease severity-dependent on repeat length.
Expression studies have focused on examining the transcript levels of DMPK, DMWD, and SIX5 in both individuals with DM1 and normal individuals. In the case of DMPK, an equal amount of unprocessed transcripts are produced from both the normal and the mutant DMPK genes , indicating that there is no interference with DMPK transcription caused by the CTG expansion. Studies involving SIX5 and DMWD have given conflicting results. Thornton and colleagues (1997) used an allele-specific RT-PCR assay and found that the expression of the CTG repeat expansion-linked SIX5 allele was reduced-in some cases approaching inactivation-compared with the other SIX5 allele. This reduction was seen with pre-mRNA, as well as with processed mRNA. Klesert and colleagues (1997) demonstrated that a DNase I hypersensitive site, shown by Otten and Tapscott (1995) to be eliminated by the CTG repeat expansion, contains an enhancer sequence for the SIX5 gene but not for the DMPK gene, and that expansion of the CTG reduces the transcription of the SIX5 allele located cis to the expansion. Data generated by Hamshere and colleagues (1997) , indicated that the cytoplasmic expression of both SIX5 and DMWD was the same in both normal and DM1 cells.
The most compelling support for the involvement of neighboring genes in DM pathogenesis came from the fact that Six5 knockout mice develop cataracts (Klesert et al. 2000; Sarkar et al. 2000) . Although cataracts are one of the clinical features of DM, the cataracts in the Six5 knockouts do not have the distinctive iridescent opacities or the posterior location that is associated with myotonic dystrophy in humans.
RNA Pathogenesis
A third hypothesized mechanism is that the enlarged CUG-containing transcripts that accumulate as foci in the nuclei of both cultured cells and biopsied tissue (Taneja et al. 1995; Davis et al. 1997 ) exert a trans-dominant effect that disrupts splicing and possibly other cellular functions (Timchenko et al. 1996a; Philips et al. 1998; Lu et al. 1999; Miller et al. 2000; Savkur et al. 2001) . Strong experimental support for the involvement of an RNA mechanism in skeletal muscle pathology came from a mouse model developed by Mankodi and colleagues (2000) . Initial attempts to develop animal models to study the effects of the expression of elongated CUG expansions in transgenic mice were hampered by infertility of the mice, which prevented successful breeding ). In 2000, Mankodi and colleagues avoided this problem by developing a mouse model in which the CTG expansion was inserted into the 3 end of the human skeletal actin gene, a gene not thought to be involved in DM1 but the expression of which is limited to skeletal muscle (Mankodi et al. 2000 ). This mouse model, which expressed an mRNA with a CUG repeat tract of ∼250 repeats was the first to develop the myotonia and the myopathic features characteristic of DM1 (Mankodi et al. 2000) . However, because the expression of the CUG-containing transcripts in this model was limited to skeletal muscle, the role of the CUG expansion in the multisystemic features of DM was not addressed.
Additive Model of DM1 Pathogenesis
Subsequently, an additive model was proposed in which each of the above mechanisms contributes to DM1 pathogenesis (Groenen and Wieringa 1998; Tapscott 2000; Filippova et al. 2001; Larkin and Fardaei 2001) , with some aspects of the disease caused by haploinsufficiency of DMPK, SIX5, and other neighboring genes and other clinical features resulting from effects of the CUG expansion in RNA. An inconsistency with the additive model of DM1 pathogenesis was that the genetic locus for DM2 maps to a different chromosome, with no known conservation between the two chromosomal regions (Ranum et al. 1998 ).
DM2 Caused by CCTG Expansion in Intron 1 of ZNF9
Given the confusion in understanding the molecular pathogenesis of DM1, the identification of a second human mutation that causes the multisystemic effects of DM and a determination of what is common to these diseases at the molecular level, provided an independent means of evaluating the pathogenic pathway(s) of DM. In 2001, we demonstrated that DM2 is also caused by a transcribed but untranslated repeat expansion-but this time a CCTG repeat expansion located in intron 1 of the zinc finger protein 9 (ZNF9) gene (MIM 116955). Although DM2 is generally a milder disease than DM1, the DM2 CCTG expansions can be much larger than DM1 CTG expansions, with alleles ranging in size from ∼75 to 11,000 CCTG repeats (mean ∼5,000 CCTGs). The smallest pathogenic size is not yet clear, because somatic instability has resulted in individuals with uncommon shorter expansions also having larger allele sizes in lymphocyte DNA (Liquori et al. 2001 ).
The DM2 CCTG expansion mutations show both somatic and intergenerational instability. In peripheral blood samples, the degree of somatic instability is so extreme that one in five DM2 expansions is not detectable by Southern analysis because of size heterogeneity. This causes a diagnostic challenge for DM2 not previously encountered with DM1 or any of the other reported microsatellite expansion disorders (Liquori et al. 2001; Day et al. 2003) . Although anticipation has been reported in DM2/PROMM families, on the basis of clinical criteria (Schneider et al. 2000; Day et al. 2003) , the expected trend of longer repeat expansions in patients with earlier ages at onset was not observed (Schneider et al. 2000; Day et al. 2003) , with the somatic instability of the repeat clearly complicating this analysis (Liquori et al. 2001) .
The DM2 repeat tract contains the complex repeat motif (TG) n (TCTG) n (CCTG) n . The CCTG portion of the repeat tract is interrupted on normal alleles, but as in other expansion disorders these interruptions are lost on affected alleles. Haplotype analysis of 228 control chromosomes identified a potential premutation allele with an uninterrupted (CCTG) 20 on a haplotype that was identical to the most common affected haplotype. Similar to some of the other microsatellite expansion disorders (Chung et al. 1993; Kunst and Warren 1994; Pulst et al. 1996; Gunter et al. 1998) , the loss of se- quence interruptions within the CCTG portion of the DM2 repeat tract may predispose alleles to further expansion (Liquori et al. 2003) .
Our 2001 discovery of the DM2 CCTG expansion allowed for further analysis of the genetic heterogeneity of DM. It now appears that most if not all families with dominant multisystemic myotonic disorders have either DM1 or DM2 expansions, with no convincing examples that would suggest the existence of a third mutation that causes a similar disorder-that is, DM3 . Families previously reported to have a form of DM or PROMM not linked to either the DM1 or DM2 loci were subsequently shown to carry the DM2 CCTG expansion . Linkage disequilibrium and haplotype analysis suggest that single founder mutations led to the CTG and CCTG expansions responsible for both DM1 and DM2 (Imbert et al. 1993; Neville et al. 1994; Chakraborty et al. 1996; Bachinski et al. 2003; Liquori et al. 2003) .
DM2: Evidence that RNA Pathogenesis Causes Multisystemic Clinical Features
The location of the CCTG expansion within intron 1 of ZNF9 is similar to the DM1 CTG expansion, in that both repeats are transcribed into RNA but do not alter the protein coding portion of a gene (Liquori et al. 2001) . The normal function of ZNF9 as a nucleic acidbinding protein (Pellizzoni et al. 1997 (Pellizzoni et al. , 1998 Shimizu et al. 2003 ) appears unrelated to any of the proteins encoded in the DM1 region of chromosome 19. Similarly, genes in the DM2 region (KIAA1160, Rab 11B, glycoprotein IX, FLJ11631, and FLJ12057) bear no obvious relationship to genes near the DM1 locus (DMPK, SIX5, DMWD, and FCGRT). Even if the DM2 expansion alters the regulation of ZNF9 and other genes in the DM2 region, it would be unlikely that alterations in the regulation of different sets of proteins at the DM1 and DM2 loci would result in diseases with such strikingly similar multisystemic features.
The first suggestion that CUG-containing transcripts were involved in DM1 pathogenesis came from FISH experiments demonstrating that CUG-containing nuclear RNA foci accumulate in DM1 cells (Taneja et al. 1995) . Evidence that DM1 and DM2 share a common pathogenic RNA mechanism comes from experiments showing that similar CCUG-containing RNA foci are found in DM2 muscle ( fig. 1) (Liquori et al. 2001 ). These results demonstrate that the CCTG expansion is expressed at the RNA level, but additional experiments are needed to determine if the RNA foci contain the entire unprocessed ZNF9 transcript or if the transcript is normally processed but the intron or the repeat tract alone resists degradation forming the RNA foci. Additional evidence that RNA foci containing the DM1 and DM2 repeat motifs behave in a similar manner is that several forms of the RNA-binding protein muscleblind (MBNL, MBLL, and MBXL) colocalize to the repeat-containing foci in both diseases (Mankodi et al. 2001; Fardaei et al. 2002) .
Although the additive model of DM1 suggested that CUG repeats in RNA cause the myotonia and muscular dystrophy of DM1, the causes of other DM featuresincluding cardiac conduction defects and cataractshad been ascribed to haploinsufficiency of genes in the DM1 region. The clinical and molecular parallels between DM1 and DM2 suggest a simpler model of DM pathogenesis (figs. 2 and 3), in which the clinical features common to both diseases-including myotonia, muscular dystrophy, cataracts, cardiac arrythmias, insulin insensitivity and diabetes, hypogammaglobulinemia, and testicular failure-are caused by the pathogenic effects of RNA containing the CUG and CCUG expansions Liquori et al. 2001) Although DM1 and DM2 phenotypes are strikingly similar, they are not identical. DM2 does not show a RNA model of DM pathogenesis. The unusual and rare multisystemic clinical parallels between DM1 and DM2 suggest a similar pathogenic mechanism. The discovery that DM2 mapped to chromosome 3 and not the DM1 region of chromosome 19 make it unlikely that regional effects of gene expression play a major role in causing the common clinical features of the disease because regional disregulation would affect different sets of genes. The discovery that a CCTG repeat expansion located on chromosome 3 which is expressed at the RNA but not the protein level causes DM2, and the observation that both CUG and CCUG repeat-containing foci accumulate in affected muscle nuclei suggests that a gain-of-function RNA mechanism underlies the clinical features common to both diseases. Specific changes in pre-mRNA splicing have been that have been associated with several genes, including the insulin receptor, the chloride channel, and cardiac troponin T, are correlated with insulin resistance, myotonia, and possibly cardiac abnormalities. (Adapted from Curr Opin Genet Dev 12:266-271.)
Figure 3
Schematic diagram of steps involved in RNA gain-offunction mechanism. CTG and CCTG expansions at the DM1 or DM2 loci result in the accumulation of CUG or CCUG repeat-containing transcripts as nuclear RNA foci. RNA-binding proteins, including CUG-BP and the muscleblind family of proteins bind to or are disregulated by the repeat-containing RNA transcripts resulting in specific trans-alterations in pre-mRNA splicing. congenital form or mental retardation that can occur in DM1 (Liquori et al. 2001 ). Downstream differences of the CUG vs. CCUG expansions could be responsible for the clinical distinctions between these diseases as could differences in temporal or spatial levels of transcripts containing the expanded repeats. A possible mechanism for congenital DM1 has been suggested by Fillipova and colleagues, who showed that methylation at the DM1 locus in congenital cases can increase expression of DMPK, resulting in higher levels of CUGcontaining transcripts and the more severe congenital phenotype (Filippova et al. 2001) . Alternatively, the differences between DM1 and DM2 could involve locusspecific genes such as DMPK, SIX5, or DMWD for DM1, and ZNF9 for DM2.
Dominant RNA Mechanism: Specific Targets of Abnormal Pre-mRNA Splicing
Evidence that a gain-of-function alteration at the RNA level plays a role in DM1 pathogenesis includes (i) the observation that an expanded repeat in the 3 UTR of DMPK mRNA inhibits myoblast differentiation (Amack et al. 1999 ); (ii) transgenic models in which 1250 CTG repeats expressed at the RNA level cause myotonia and muscular dystrophy (Mankodi et al. 2000; Seznec et al. 2001 ); (iii) CUG-and CCUG-containing transcripts that accumulate as RNA foci alter the regulation or localization of CUG-binding proteins, including CUG-BP (Timchenko et al. 1996a ) and three different forms of muscleblind (Miller et al. 2000; Fardaei et al. 2002) ; (iv) altered CUG-and CCUG-induced splicing changes that are directly related to phenotypic features of DM. A recent report using cell-culture models suggests that CUG RNA expansions bind and sequester transcription factors in DM1 and may disrupt gene regulation including the chloride channel ClC-1 (Ebralidze et al. 2004 ), but the role of altered gene transcription in DM pathogenesis is not clear and will need further investigation.
The currently identified splicing alterations are described in further detail below.
Cardiac Troponin T (cTNT)
Initial efforts to understand how the DM1 CUG expansion expressed at the RNA level could mediate a trans-dominant effect focused on the identification of RNA-binding proteins that could bind to CUG repeat motifs. The first of these proteins to be isolated and described in detail was CUG-binding protein (CUG-BP) (Timchenko et al. 1996a (Timchenko et al. , 1996b . In a landmark discovery in 1998, Phillips and colleagues (1998) reported that CUG-BP, a conserved heterogeneous nuclear ribonucleoprotein, could mediate a trans-dominant effect of excess CUG repeat-containing RNA by disregulating the alternative splicing of cardiac troponin T (cTNT). CUG-BP was shown to bind to intronic CUG repeat sequences in human cardiac troponin T (cTNT) pre-mRNA, which are normally used as splicing signals. The presence of excess numbers of CUG repeats in transfection studies and in DM1 cardiac and skeletal muscle cultures cause the preferential inclusion of exon 5, which is a splice form produced during the early development of heart and skeletal muscle but not in adult heart. This typical splicing pattern of cTNT is disrupted in DM1 striated muscle and in transfected cells expressing either CUG-BP protein or elongated CUG-containing transcripts. This was the first demonstrated splicing target of CUG-BP and the first demonstration that the presence of elongated CUG repeat motifs lead to trans alterations in gene splicing (Philips et al. 1998) .
Insulin Receptor (IR)
A classic clinical feature in both DM1 and DM2 patients is insulin resistance; the reduced insulin response in skeletal muscle predisposes DM patients to diabetes. Savkur et al. (2001) demonstrated that alternative splicing of the insulin receptor (IR) pre-mRNA is aberrantly regulated in DM1 skeletal muscle tissue, resulting in predominant expression of the insulin insensitive nonmuscle splice form lacking exon 11. Steady state levels of CUG-BP are increased in skeletal muscle of DM1 patients and disregulation of CUG-BP is thought to mediate an IR alternative splicing switch by the binding to an intronic element upstream of the alternatively spliced exon 11. These results support a model in which increased expression of a splicing regulator contributes to insulin resistance in DM1 by affecting IR alternative splicing (Savkur et al. 2001) .
Muscle-Specific Chloride Channel
A classic feature of both DM1 and DM2 is myotonia, in which voluntary muscle contraction is followed by involuntary repetitive firing of action potentials that delay a patient's ability to relax muscle (Harper 2001) . Using skeletal muscle from a transgenic mouse model of DM1, colleagues (2000, 2002) showed that expression of expanded CUG repeats in skeletal muscle reduces the transmembrane chloride conductance to levels consistent with those expected to cause myotonia. Additional studies determined that aberrant splicing of Clc-1, the main chloride channel in muscle, resulting in loss of Clc-1 protein from the surface membrane (Mankodi et al. 2002) . Similar splicing alterations were observed in skeletal muscle from both DM1 and DM2 patients (Charlet et al. 2002; Mankodi et al. 2002) . Charlet and colleagues (2002) demonstrated that CUG-BP, which is elevated in DM1 skeletal muscle, binds to the ClC-1 pre-mRNA, and overexpression of CUG-BP in transfected cells reproduces the aberrant pattern of ClC-1 splicing. Both groups propose that disruptions in alternative splicing regulation of ClC-1 causes a channelopathy and membrane hyperexcitability, leading to the classic DM feature of myotonia (Charlet et al. 2002; Mankodi et al. 2002) .
Tau and Myotubularin
Splicing alterations in the microtubule-associated tau pre-mRNA have been observed in CNS tissue from patients with DM1 and in a murine model described by Seznec and colleagues (2001) , which may underlie various CNS alterations in both diseases. Also, muscle-specific changes in alternative splicing of the myotubularin-related 1 (MTMR1) gene are observed in congenital DM1 muscle cells in culture and in skeletal muscle samples from patients with congenital-onset DM1. These results suggest that MTMR1 plays a role in muscle formation and represents a novel target for abnormal mRNA splicing in myotonic dystrophy that may be responsible for the profound muscle atrophy of congenital DM1 (Buj-Bello et al. 2002) .
Are RNA Foci Pathogenic or Protective?
Neurodegenerative diseases, such as Alzheimer disease and those caused by polyglutamine expansions, result in protein aggregates or plaques and tangles that accumulate in affected tissues and have led investigators to debate their role in disease pathogenesis (Hsiao et al. 1995; Klement et al. 1998) . Similar discussions in the DM field revolve around the role of RNA foci in disease pathogenesis. CUG-BP, the first RNA-binding protein with a demonstrated pathogenic effect, has been shown to bind to single-stranded CUG repeats. In contrast with the muscleblind family of proteins, CUG-BP does not colocalize with the nuclear RNA foci in DM1 and DM2. Although it appeared possible that both groups of proteins play a role in the pathogenic effects of DM, colocalization of a protein to the ribonuclear inclusions did not appear to be necessary to cause a pathogenic effect.
Direct evidence supporting the hypothesis that sequestration of muscleblind in CUG and CCUG containing RNA foci plays a central role in disease pathogenesis comes from a recently developed muscleblind knockout model of myotonic dystrophy. Kanadia and colleagues showed that disruption of the mouse Mbnl1 gene leads to muscle, eye, and RNA-splicing abnormalities that are characteristic of DM1 and DM2 in humans (Kanadia et al. 2003) .
Data now indicate that overexpression of CUG-BP and depletion of Mbnl1 both can cause specific alternative-splicing changes. Previous studies have reported that expression of elongated CUG-containing transcripts result in increased levels of CUG-BP through an unknown mechanism. In contrast, the sequestration of Mbnl1 in CUG and CCUG RNA foci has been proposed as a mechanism that results in Mbnl1 depletion. It now appears that both of these proteins play a role in affecting alternative splicing and that, in the case of ClC1, changes through antagonistic effects in which CUG-BP promotes the inclusion of exons that are normally favored during fetal development, whereas the normal function of Mbnl1 is to favor splice forms expressed in adults. These data predict that overexpression of CUG-BP or depletion of Mbnl1 would both result in the splicing alterations and that changes in the regulation of either these proteins can cause downstream splicing changes that have now been shown to be characteristic of the myotonic dystrophies.
Other Noncoding Disorders
Although the striking clinical and molecular parallels between DM1 and DM2 demonstrate that RNA pathogenesis plays a much broader role in the multisystemic features of myotonic dystrophy than previously suspected, noncoding microsatellite expansions for SCA8 (Koob et al. 1999 ) and SCA10 (Matsuura et al. 2000) were identified before the DM2 expansion. The pathogenic mechanism of the DM1 and DM2 expansions are evident only because they cause such a distinctive phe-notype. Molecular parallels between the SCA8 CUG repeat and the DM1 and DM2 repeats suggest the possibility that the known toxic properties of transcripts with elongated CUGs underlie the cerebellar degeneration in SCA8 (Ranum and Day 2002) . Although, in SCA10, it is possible that the enormous ATTCT expansion in an intron of a gene may cause disease through haploinsufficiency, the dominant inheritance pattern and the fact the expression of the SCA10 transcript does not appear to be reduced in affected individuals (Matsuura et al. 2000 ) make this potential mechanism less likely. Parallels between SCA10 and the RNA mechanism involved in DM1, DM2, and possibly SCA8 suggest a gain-of-function mechanism at the RNA level could be involved. Unlike SCA8, the gene that harbors the mutation for SCA10 is ubiquitously expressed, indicating that, if a toxic RNA mechanism is involved, secondary proteins that interact with the AUUCU repeat motif may confer organ-specific pathogenicity (Matsuura et al. 2000) . FMR premutation alleles that have recently been reported to be associated with a tremor-ataxia syndrome may involve a similar RNA mechanism (Brunberg et al. 2002; Aziz et al. 2003; Jacquemont et al. 2003) .
Conclusions
The clinical and molecular parallels of DM1 and DM2 demonstrate the multisystemic effects of CUG and CCUG expansions. A detailed description of trans-dominant splicing alterations of genes relevant to the DM phenotype is emerging, providing a convincing model of how these RNA expansions cause myotonic dystrophy. In other microsatellite-expansion diseases, including SCA8 and SCA10, transcribed noncoding expansions cause very different CNS phenotypes, suggesting that dominant RNA mechanisms may be a general cause of disease.
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